GLD Acquires Seelos Therapeutics’ Assets, Strengthening GLD’s Growing Life Sciences Portfolio
GLD Announces Successful Closing of Seelos Assets; Includes Ketamine and Trehalose Programs Advancing into Phase 3 Clinical Trials
Weekly newsletter
Join our community and never miss out on exciting opportunities.